Medios AG stock analysis
Medios AG (0QB4) Share Price & Analysis
0QB4 Stock Chart & Stats
- Day’s Range
- EUR 10.40 - EUR 10.88
- 52-Week Range
- EUR 10.00 - EUR 17.44
- Previous Close
- EUR 10.88
- Volume
- N/A
- Average Volume (3M)
- 942
- Market Cap
- EUR 265.26M
- Enterprise Value
- EUR 412.89M
- Total Cash (Recent Filing)
- EUR 83.16M
- Total Debt (Recent Filing)
- EUR 200.02M
- Price to Earnings (P/E)
- 23.6
- Beta
- 0.62
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth
Broad-based revenue growth across all business segments indicates expanding demand rather than reliance on one activity. Continued momentum in specialty therapies and pharmaceutical supply can support scale benefits, strengthen customer relationships, and provide a durable platform for further organic and inorganic growth.
Efficiency And Margin Recovery
Identified cost savings and improving margins in patient-specific therapies show that management is taking concrete steps to improve operating economics. If sustained, these initiatives can offset pricing pressure, increase earnings resilience, and convert the company’s revenue growth into stronger long-term profitability.
Scalable Operating Capacity
Existing laboratory capacity and the ability to absorb customers without increasing operational personnel suggest useful operating leverage. This infrastructure can support additional compounding volumes, improve utilization of the current footprint, and reduce the need for near-term capacity investment as demand grows.
Bears Say
Thin Profitability
Very thin profitability leaves Medios highly sensitive to pricing, product mix, operating costs, and other changes below the revenue line. The decline in net income despite strong sales growth indicates that expansion is not yet translating proportionately into shareholder earnings, limiting financial resilience.
Weaker Cash Generation
The sharp decline in operating cash flow and free cash flow weakens the company’s ability to fund growth, acquisitions, debt service, and shareholder returns internally. Management’s expectation for roughly EUR 40m of 2026 operating cash flow also indicates that cash conversion may remain below prior levels.
Pricing And Regulatory Pressure
Pricing pressure directly threatens margins in a business that already operates with limited profitability. Potentially earlier biosimilar regulation adds uncertainty to future reimbursement economics, making it harder to protect earnings unless efficiency gains, product mix, or negotiated pricing can offset the impact.
Medios AG News
0QB4 FAQ
What was Medios AG’s price range in the past 12 months?
What is Medios AG’s market cap?
When is Medios AG’s upcoming earnings report date?
How were Medios AG’s earnings last quarter?
Is Medios AG overvalued?
Does Medios AG pay dividends?
What is Medios AG’s EPS estimate?
How many shares outstanding does Medios AG have?
What happened to Medios AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medios AG?
What is the TipRanks Smart Score and how is it calculated?
Medios AG Stock Smart Score
Company Description
Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Thomas Meier
- Employees
- 982
- Website
- medios.group
- Address
- Heidestrasse 9, Berlin, BE, 10557, DE
Medios AG (0QB4) Earnings & Revenues
0QB4 Company Deck
0QB4 Earnings Call
Earnings Call SentimentPositive
The call had a positive overall tone. Revenue growth was broad-based, patient-specific therapies showed clear margin improvement, operational-efficiency measures were producing savings, financing was strengthened, and full-year guidance was confirmed. These positives outweighed ongoing pricing pressure, lower margins and earnings, weaker operating cash flow, elevated taxes, and regulatory uncertainty.
View all GB:0QB4 earnings summaries0QB4 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 0 | 0 | 12 |








